Literature DB >> 11006027

Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary.

G Cantuaria1, A Magalhaes, M Penalver, R Angioli, P Braunschweiger, O Gomez-Marin, R Kanhoush, C Gomez-Fernandez, M Nadji.   

Abstract

OBJECTIVE: Cancer cells have increased rates of glucose metabolism when compared to normal cells. One of the mechanisms proposed for the accelerated glucose use in malignant cells is the overexpression of glucose transporters. In this study we evaluated the expression of the GLUT-1 glucose transporter in borderline and malignant epithelial neoplasms of the ovary.
METHODS: Histologic sections of tumor tissues from 21 borderline and 82 malignant epithelial neoplasms of the ovary were stained for GLUT-1 using polyclonal GLUT-1 antibody (Dako, Carpinteria, CA) and the labeled streptavidin biotin procedure. DAB was used as chromagen and tissues were counterstained with hematoxylin.
RESULTS: Normal ovarian surface epithelial cells were either negative or weakly positive. Of the 82 carcinomas, 81 (98.8%) were positive for GLUT-1. The staining intensity was significantly associated with the grade of tumor (P = 0.001). Of the 21 borderline neoplasms, 20 (95.2%) were positive for GLUT-1. Carcinomas had a significantly stronger stain than borderline tumors (P = 0.0001). The intensity of the stain was also stronger in serous carcinomas compared to other subtypes (P = 0. 0001). Positive cells demonstrated a cytoplasmic membrane staining that was more intense in tumor cells farther away from blood supply.
CONCLUSION: Overexpression of the GLUT-1 transporter is associated with the histology and grade of the tumors. Our findings show a progressive increase in the expression of the GLUT-1 transporter from the borderline tumor to the high-grade carcinomas. These data suggest that the expression of this transporter may be closely related to the malignant transformation of epithelial ovarian tumors. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11006027     DOI: 10.1006/gyno.2000.5910

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays.

Authors:  Rachel Airley; Andrew Evans; Ali Mobasheri; Stephen M Hewitt
Journal:  Ann Anat       Date:  2010-03-24       Impact factor: 2.698

Review 2.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

3.  ¹⁸F-fluoro-2-deoxyglucose uptake on PET CT and glucose transporter 1 expression in colorectal adenocarcinoma.

Authors:  Ran Hong; Sung-Chul Lim
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

4.  Functional properties and genomics of glucose transporters.

Authors:  Feng-Qi Zhao; Aileen F Keating
Journal:  Curr Genomics       Date:  2007-04       Impact factor: 2.236

5.  Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma.

Authors:  Ubaldo E Martinez-Outschoorn; Renee M Balliet; Zhao Lin; Diana Whitaker-Menezes; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2012-10-09       Impact factor: 4.534

6.  2-deoxy-2-[F-18]fluoro-D-glucose accumulation in ovarian carcinoma cell lines.

Authors:  A M Lutz; P Ray; J K Willmann; Charles Drescher; S S Gambhir
Journal:  Mol Imaging Biol       Date:  2007 Sep-Oct       Impact factor: 3.488

7.  Evaluating the expression of GLUT-1 in oral leukoplakia.

Authors:  Daffney Mano Doss; Madhava Nirmal; R Saravanan; A Venkatesh
Journal:  J Oral Maxillofac Pathol       Date:  2020-09-09

8.  An up-to-date anti-cancer treatment strategy focusing on HIF-1alpha suppression: its application for refractory ovarian cancer.

Authors:  Mariko Fujita; Masanori Yasuda; Kanae Kitatani; Masaki Miyazawa; Kenichi Hirabayashi; Susumu Takekoshi; Tetsuji Iida; Takeshi Hirasawa; Masaru Murakami; Mikio Mikami; Isamu Ishiwata; Michio Shimizu; R Yoshiyuki Osamura
Journal:  Acta Histochem Cytochem       Date:  2007-12-18       Impact factor: 1.938

9.  Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16alpha-18F-fluoro-17beta-estradiol PET.

Authors:  Yoshio Yoshida; Tetsuji Kurokawa; Tetuya Tsujikawa; Hidehiko Okazawa; Fumikazu Kotsuji
Journal:  J Ovarian Res       Date:  2009-06-16       Impact factor: 4.234

10.  Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment.

Authors:  Chrysi Xintaropoulou; Carol Ward; Alan Wise; Suzanna Queckborner; Arran Turnbull; Caroline O Michie; Alistair R W Williams; Tzyvia Rye; Charlie Gourley; Simon P Langdon
Journal:  BMC Cancer       Date:  2018-06-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.